Mirum Pharmaceuticals Inc - Asset Resilience Ratio
Mirum Pharmaceuticals Inc (MIRM) has an Asset Resilience Ratio of 6.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Mirum Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check MIRM PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Mirum Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mirum Pharmaceuticals Inc (MIRM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $61.35 Million | 6.89% |
| Total Liquid Assets | $61.35 Million | 6.89% |
Asset Resilience Insights
- Limited Liquidity: Mirum Pharmaceuticals Inc maintains only 6.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mirum Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Mirum Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Mirum Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.28% | $86.64 Million | $842.81 Million | +1.66pp |
| 2024-12-31 | 8.62% | $57.81 Million | $670.75 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $646.62 Million | -- |
| 2022-12-31 | 35.06% | $123.72 Million | $352.91 Million | -7.43pp |
| 2021-12-31 | 42.49% | $125.20 Million | $294.65 Million | +5.24pp |
| 2020-12-31 | 37.26% | $89.73 Million | $240.86 Million | -34.10pp |
| 2019-12-31 | 71.36% | $104.69 Million | $146.71 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $51.98 Million | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more